×
戻る Agenda
Session 3 Tracks 1 and 2: Regulatory Considerations of Novel Conjugates: Translational and Clinical Pharmacology Perspectives
Session Chair(s)
Louis St. L. O'Dea, MD
Independent Consultant
United States
Patrik Andersson, PHD
Principal Scientist, Discovery Safety Specialist
AstraZeneca R&D, Sweden
Session 3 Tracks 1 and 2: Regulatory Considerations of Novel Conjugates: Translational and Clinical Pharmacology Perspectives